Kemeny NE - Search Results

1

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX. Saltz LB, et al. Among authors: kemeny ne. J Clin Oncol. 2007 Oct 10;25(29):4557-61. doi: 10.1200/JCO.2007.12.0949. Epub 2007 Sep 17. J Clin Oncol. 2007. PMID: 17876013 Clinical Trial.

2

Regional chemotherapy of colorectal cancer.

Kemeny NE. Kemeny NE. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1271-6. doi: 10.1016/0959-8049(95)00162-c. Eur J Cancer. 1995. PMID: 7577035 Review.

3

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, André AM, Grossano DD, Bertino JR. Conti JA, et al. Among authors: kemeny ne. Cancer. 1995 Feb 1;75(3):769-74. doi: 10.1002/1097-0142(19950201)75:3<769::aid-cncr2820750304>3.0.co;2-5. Cancer. 1995. PMID: 7828126 Clinical Trial.

4

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C. Conti JA, et al. Among authors: kemeny ne. J Clin Oncol. 1996 Mar;14(3):709-15. doi: 10.1200/JCO.1996.14.3.709. J Clin Oncol. 1996. PMID: 8622015

5

Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.

Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ. Welt S, et al. Among authors: kemeny ne. J Clin Oncol. 1996 Jun;14(6):1787-97. doi: 10.1200/JCO.1996.14.6.1787. J Clin Oncol. 1996. PMID: 8656247 Clinical Trial.

6

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP. Saltz LB, et al. Among authors: kemeny ne. J Clin Oncol. 1996 Nov;14(11):2959-67. doi: 10.1200/JCO.1996.14.11.2959. J Clin Oncol. 1996. PMID: 8918493 Clinical Trial.

7

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP. Saltz LB, et al. Among authors: kemeny ne. Cancer. 1997 Nov 1;80(9):1727-32. doi: 10.1002/(sici)1097-0142(19971101)80:9<1727::aid-cncr5>3.0.co;2-b. Cancer. 1997. PMID: 9351540 Clinical Trial.

8

Phase II trial of docetaxel (Taxotere) for untreated advanced colorectal carcinoma.

Clark TB, Kemeny NE, Conti JA, Huang Y, Andre AM, Stockman J. Clark TB, et al. Among authors: kemeny ne. Cancer Invest. 1998;16(5):314-8. doi: 10.3109/07357909809084650. Cancer Invest. 1998. PMID: 9627678 Clinical Trial.

9

Hepatic arterial chemotherapy in metastatic colorectal patients.

Kemeny NE, Ron IG. Kemeny NE, et al. Semin Oncol. 1999 Oct;26(5):524-35. Semin Oncol. 1999. PMID: 10528900 Review.

10

Hepatic arterial therapy for the treatment of metastatic colorectal cancer.

Kemeny NE. Kemeny NE. Semin Oncol. 2000 Oct;27(5 Suppl 10):126-31. Semin Oncol. 2000. PMID: 11049044 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

199 results

Search Page